BI-3406

BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2].

Product Specifications

CAS Number

[2230836-55-0]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

P38 MAPK; Ras; SOS1

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sos1-in-2.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)

Smiles

CC1=NC(N[C@@H](C2=CC(C(F)(F)F)=CC(N)=C2)C)=C3C=C(O[C@@H]4COCC4)C(OC)=CC3=N1

Molecular Formula

C23H25F3N4O3

Molecular Weight

462.46

Precautions

H302, H312, H332

References & Citations

[1]Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.|[2]Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.